• Applied Workflows with Angiotensin I in Cardiovascular Resea

  2026-04-22

  Harnessing Angiotensin I (Asp-Arg-Val-Tyr-Ile-His-Pro-Phe-His-Leu) enables precise modeling of the renin-angiotensin system for cardiovascular and neuroendocrine research. This guide unpacks advanced experimental workflows, cross-domain insights, and troubleshooting strategies that leverage APExBIO’s high-purity peptide for robust, reproducible data.

• Angiotensin Peptides Enhance SARS-CoV-2 Spike–AXL Binding

  2026-04-22

  This study reveals that naturally occurring angiotensin peptides, including the fragment Angiotensin 1/2 (1-6), significantly enhance the binding of the SARS-CoV-2 spike protein to the AXL receptor, potentially impacting viral pathogenesis. These findings introduce a mechanistic link between the renin–angiotensin system and viral entry, with important implications for cardiovascular and infectious disease research.

• Niclosamide: Applied STAT3 Inhibition for Cancer Research Wo

  2026-04-21

  Niclosamide, a potent STAT3 signaling pathway inhibitor, enables precise control of cell cycle arrest and apoptosis in cancer models. This article delivers stepwise protocol enhancements, troubleshooting guidance, and real-world data, empowering advanced oncology research with APExBIO’s trusted reagent.

• EZ Cap™ Cas9 mRNA (m1Ψ): Engineering Immune-Evasive Precisio

  2026-04-21

  Explore how EZ Cap™ Cas9 mRNA (m1Ψ) leverages mRNA Cap1 structure and N1-Methylpseudo-UTP modification for immune-evasive, high-fidelity genome editing. This article uniquely focuses on the interplay between mRNA design, nuclear export, and practical workflow optimization.

• PPARα-Driven TF Upregulation by Linoleic Acid in pLELC Progr

  2026-04-20

  This study reveals that linoleic acid (LA) promotes tumor progression in primary pulmonary lymphoepithelioma-like carcinoma (pLELC) by upregulating tissue factor (TF) expression through PPARα activation. Using proteomics, metabolomics, and patient-derived xenograft models, the authors highlight TF as a potential therapeutic target and illuminate the metabolic-immune interplay in pLELC tumor microenvironment.

• Pazopanib Hydrochloride: Quantitative Insights for Advanced

  2026-04-20

  Explore how Pazopanib Hydrochloride (GW786034) enables rigorous, quantitative evaluation of anti-angiogenic strategies in cancer research. This article provides protocol-level guidance and a unique systems biology perspective, distinguishing itself from prior reviews.

• Sulfo-Cy5 Carboxylic Acid: Fluorescent Dye for Life Sciences

  2026-04-19

  Sulfo-Cy5 carboxylic acid stands out as a highly water-soluble, low-quenching fluorescent dye that excels in protein and peptide labeling for robust imaging in aqueous environments. Its proven performance in neuroscience and mucosal immunity research makes it an essential tool for advanced experimental workflows demanding sensitivity and reproducibility.

• WM-8014 as a Precision KAT6A Inhibitor in Cancer Biology Res

  2026-04-18

  WM-8014 stands apart as a reversible, highly selective KAT6A inhibitor that enables robust oncogene-induced senescence induction and cell cycle arrest assays without general cytotoxicity. This article demystifies its protocol setup, advanced applications, and troubleshooting, empowering researchers to unlock new epigenetic dependencies and refine their cancer biology workflows.

• Firefly Luciferase mRNA: Precision Reporter for Robust Assay

  2026-04-17

  Firefly Luciferase mRNA (ARCA, 5mCTP, ΨUTP) empowers researchers with a highly stable, immune-silent, and translation-optimized bioluminescent reporter for gene expression, cell viability, and in vivo imaging assays. Leveraging advanced cap and nucleotide modifications, this reagent from APExBIO sets a new standard for reproducibility and sensitivity in experimental and translational workflows.

• Birinapant (TL32711) in Apoptosis Research: Workflow & Troub

  2026-04-16

  Birinapant (TL32711) offers bench scientists a precision tool for apoptosis induction in cancer cells, overcoming resistance via robust pan-IAP antagonism. This guide delivers actionable protocols, troubleshooting insights, and strategic workflow enhancements for translational oncology, grounded in the latest mechanistic and applied evidence.

• MRT68921: Strategic Autophagy Inhibition for Translational I

  2026-04-15

  This article synthesizes mechanistic insights on autophagy regulation with actionable guidance for translational researchers. Highlighting recent paradigm shifts in AMPK-ULK1 signaling, it positions MRT68921—a dual autophagy kinase ULK1/2 inhibitor from APExBIO—as a critical tool for dissecting autophagy in preclinical models. The piece integrates protocol recommendations, competitive perspectives, and a visionary outlook on next-generation autophagy modulation.

• MPC-Driven Lactate and Histone Lactylation in Tumor Immunity

  2026-04-14

  This study reveals how mitochondrial pyruvate carrier (MPC) downregulation elevates lactate in the tumor microenvironment, driving histone lactylation in dendritic cells and impairing antitumor immunity. The findings clarify a key epigenetic mechanism linking tumor metabolism to immune suppression, with direct implications for immunotherapy strategies.

• Bovine Insulin: Strategic Leverage in Translational Cell Mod

  2026-04-13

  Explore how bovine insulin from APExBIO underpins cutting-edge translational research by enhancing cell proliferation, enabling metabolic precision, and supporting mechanistic modeling of disease. This article bridges cellular biology, experimental rigor, and real-world clinical applications—integrating evidence from cell culture advances and recent insights into stress pathways and fibrosis.

• HRP Goat Anti-Rabbit IgG (H+L) Antibody: Technical Use Guide

  2026-04-13

  The HRP Goat Anti-Rabbit IgG (H+L) Antibody (SKU K1223) enables specific and sensitive detection of rabbit primary antibodies in immunoassays such as ELISA, Western blot, and immunohistochemistry. Designed for workflows requiring minimal cross-reactivity and high signal amplification, it is not suitable for diagnostic or medical applications, nor for detection of non-rabbit IgG targets.

• G007-LK Tankyrase 1/2 Inhibitor: Precision for Wnt/β-catenin

  2026-04-12

  G007-LK sets a new benchmark for pathway-specific inhibition in APC mutation colorectal cancer and Hippo pathway research. Its nanomolar potency, reproducible β-catenin degradation, and robust in vitro/in vivo efficacy make it the tankyrase 1/2 inhibitor of choice for dissecting oncogenic signaling and advancing therapeutic workflows.

11220 records 1/748 page Next 12345 下5页 Last page